Paulien G Westhoff1, Alexander de Graeff2, Evelyn M Monninkhof3, Jacqueline Pomp4, Marco van Vulpen5, Jan Willem H Leer6, Corrie A M Marijnen7, Yvette M van der Linden7. 1. Department of Radiotherapy, University Medical Center Utrecht, Utrecht, The Netherlands. Electronic address: p.g.westhoff@umcutrecht.nl. 2. Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands. 3. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. 4. Department of Radiotherapy, Reinier de Graaf Gasthuis, Delft, The Netherlands. 5. Department of Radiotherapy, University Medical Center Utrecht, Utrecht, The Netherlands. 6. Department of Radiotherapy, University Medical Center Nijmegen, Nijmegen, The Netherlands. 7. Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
Abstract
PURPOSE: To study quality of life (QoL) in responders and nonresponders after radiation therapy for painful bone metastases; and to identify factors predictive for a pain response. PATIENTS AND METHODS: The prospectively collected data of 956 patients with breast, prostate, and lung cancer within the Dutch Bone Metastasis Study were used. These patients, irradiated for painful bone metastases, rated pain, QoL, and overall health at baseline and weekly afterward for 12 weeks. Using generalized estimating equations analysis, the course of QoL was studied, adjusted for primary tumor. To identify predictive variables, proportional hazard analyses were performed, taking into account death as a competing risk, and C-statistics were calculated for discriminative value. RESULTS: In total, 722 patients (76%) responded to radiation therapy. During follow-up, responders had a better QoL in all domains compared with nonresponders. Patients with breast or prostate cancer had a better QoL than patients with lung cancer. In multivariate analysis, baseline predictors for a pain response were breast or prostate cancer as primary tumor, younger age, good performance status, absence of visceral metastases, and using opioids. The discriminative ability of the model was low (C-statistic: 0.56). CONCLUSIONS: Responding patients show a better QoL after radiation therapy for painful bone metastases than nonresponders. Our model did not have enough discriminative power to predict which patients are likely to respond to radiation therapy. Therefore, radiation therapy should be offered to all patients with painful bone metastases, aiming to decrease pain and improve QoL.
RCT Entities:
PURPOSE: To study quality of life (QoL) in responders and nonresponders after radiation therapy for painful bone metastases; and to identify factors predictive for a pain response. PATIENTS AND METHODS: The prospectively collected data of 956 patients with breast, prostate, and lung cancer within the Dutch Bone Metastasis Study were used. These patients, irradiated for painful bone metastases, rated pain, QoL, and overall health at baseline and weekly afterward for 12 weeks. Using generalized estimating equations analysis, the course of QoL was studied, adjusted for primary tumor. To identify predictive variables, proportional hazard analyses were performed, taking into account death as a competing risk, and C-statistics were calculated for discriminative value. RESULTS: In total, 722 patients (76%) responded to radiation therapy. During follow-up, responders had a better QoL in all domains compared with nonresponders. Patients with breast or prostate cancer had a better QoL than patients with lung cancer. In multivariate analysis, baseline predictors for a pain response were breast or prostate cancer as primary tumor, younger age, good performance status, absence of visceral metastases, and using opioids. The discriminative ability of the model was low (C-statistic: 0.56). CONCLUSIONS: Responding patients show a better QoL after radiation therapy for painful bone metastases than nonresponders. Our model did not have enough discriminative power to predict which patients are likely to respond to radiation therapy. Therefore, radiation therapy should be offered to all patients with painful bone metastases, aiming to decrease pain and improve QoL.
Authors: Joanne M van der Velden; Anne L Versteeg; Helena M Verkooijen; Charles G Fisher; Edward Chow; F Cumhur Oner; Marco van Vulpen; Lorna Weir; Jorrit-Jan Verlaan Journal: Oncologist Date: 2017-05-03
Authors: Q M J van der Vliet; N R Paulino Pereira; S J Janssen; F J Hornicek; M L Ferrone; J A M Bramer; C N van Dijk; J H Schwab Journal: Clin Orthop Relat Res Date: 2016-10-17 Impact factor: 4.176
Authors: D Harding; S L Giles; M R D Brown; G R Ter Haar; M van den Bosch; L W Bartels; Y-S Kim; M Deppe; N M deSouza Journal: Clin Oncol (R Coll Radiol) Date: 2018-01-06 Impact factor: 4.126
Authors: Ragnhild Habberstad; Trude Camilla Salvesen Frøseth; Nina Aass; Tatiana Abramova; Theo Baas; Siri Tessem Mørkeset; Augusto Caraceni; Barry Laird; Jason W Boland; Romina Rossi; Elena Garcia-Alonso; Hanne Stensheim; Jon Håvard Loge; Marianne Jensen Hjermstad; Ellen Bjerkeset; Asta Bye; Jo-Åsmund Lund; Tora Skeidsvoll Solheim; Ola Magne Vagnildhaug; Cinzia Brunelli; Jan Kristian Damås; Tom Eirik Mollnes; Stein Kaasa; Pål Klepstad Journal: BMC Palliat Care Date: 2018-09-28 Impact factor: 3.234
Authors: Katie L Spencer; Joanne M van der Velden; Erin Wong; Enrica Seravalli; Arjun Sahgal; Edward Chow; Jorrit-Jan Verlaan; Helena M Verkooijen; Yvette M van der Linden Journal: J Natl Cancer Inst Date: 2019-10-01 Impact factor: 13.506
Authors: Rachel McDonald; Keyue Ding; Michael Brundage; Ralph M Meyer; Abdenour Nabid; Pierre Chabot; Genevieve Coulombe; Shahida Ahmed; Joda Kuk; A Rashid Dar; Aamer Mahmud; Alysa Fairchild; Carolyn F Wilson; Jackson S Y Wu; Kristopher Dennis; Carlo DeAngelis; Rebecca K S Wong; Liting Zhu; Stephanie Chan; Edward Chow Journal: JAMA Oncol Date: 2017-07-01 Impact factor: 31.777
Authors: Joanne M van der Velden; Yvette M van der Linden; Anne L Versteeg; Jorrit-Jan Verlaan; A Sophie Gerlich; Bart J Pielkenrood; Nicolien Kasperts; Helena M Verkooijen Journal: J Radiat Oncol Date: 2018-11-10